Obesity Interventions – Market Insights – United States

The US obesity intervention device market will grow strongly over the forecast period. Market growth will be driven by rising volumes of bariatric and endoluminal procedures. The internal closure device market will continue to generate the highest proportion of obesity intervention device revenues over the forecast period due to their applicability in the majority of surgical procedures. However, continued innovation and product launches in the surgical stapler space will also support the penetration of these devices into bariatric surgeries. Moving forward, market growth will be driven by the introduction of new technologies and the FDA approval of innovative products. These advanced products are anticipated to command higher prices and contribute to strong market growth over the forecast period.

This Medtech 360 report provides comprehensive data and analysis on the state of the obesity intervention market in the US from 2019 through 2032.

GLP-1 receptor agonists have been seeing growing adoption among the US patient population in recent years.

How will the adoption of GLP-1 receptor agonists affect the US obesity intervention market?

What will be the impact of rising use of GLP-1 receptor agonist on the bariatric surgery procedures?

There’s a growing trend among US physicians to adopt novel bariatric procedures for weight loss.

What are these new procedures?

What will be the expected growth rate of these procedures over the forecast period?

New competitors are expected to enter this space within the forecast period.

Who are these competitors and what products are they bringing to the market?

Which segments are seeing the most incoming competitors?

Table of contents